Directed evolution of bicyclic peptides for therapeutic application

9Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Many naturally occurring cyclic peptides or derivatives thereof are used as therapeutics such as the human hormones vasopressin and oxytocin or the antibiotics vancomycin and daptomycin. The success of cyclic peptide therapeutics is based on their ability to bind with high affinity, their good target selectivity and their low toxicity. As nature provides cyclic peptides to only a small number of disease targets, strategies have been developed to generate cyclic peptide ligands with tailored specificity de novo. Our laboratory is specialized on the directed evolution of bicyclic peptide ligands by phage display. In this article, we review our recent work to in vitro evolve bicyclic peptide antagonists, the binding and pharmacokinetic properties of bicyclic peptides, as well as efforts to generate bicyclic peptides for therapeutic application. © Schweizerische Chemische Gesellschaft.

Cite

CITATION STYLE

APA

Diderich, P., & Heinis, C. (2013). Directed evolution of bicyclic peptides for therapeutic application. Chimia. Swiss Chemical Society. https://doi.org/10.2533/chimia.2013.910

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free